ADMA

Rating buyAI Memo

ADMA Biologics

As of 2026-08-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

6‑12m

Key catalyst

ACAAI real-world evidence update • 2026-11-15

Base target: $11 / p=50% prob

Biggest risk

Revenue growth remains modest because Bivigam is under competitive pressure. Guidance depends on sustained Asceniv momentum, while R&D spending for SG-001 is expected to increase. No reliable post-print analyst revision or target-change signal is available.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Asceniv growth, improving utilization, strong margins, cash generation, and reiterated FY2026 guidance support continued execution upside [#SEC-8K-2026-08-05]. The ACAAI real-world evidence update could further aid adoption.

Research note

Recommendation

buy

Confidence

medium

As of

2026-08-17

Base target

$11

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Bivigam competitive and pricing pressure
SG-001 pre-IND development milestone
Asceniv growth, improving utilization, strong margins, cash generation, and reiterated FY2026 guidance support continued execution upside [#SEC-8K-2026-08-05].

BearKey bullets

Asceniv utilization growth or prescriber adoption could slow, weakening the main commercial growth driver.
Bivigam demand and pricing remain pressured by competition, discounting, and market supply dynamics.
Higher R&D and operating expenses could pressure near-term profitability.

WatchKey bullets

ACAAI real-world evidence update

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $11 (p=50%)

Target spread vs base: +13% / -31%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $11 (p=50%)Bear Target: $8 (p=25%)

Commentary

News tone is constructive on Asceniv growth, margin expansion, and reiterated guidance, but mixed because Q2 revenue reportedly missed consensus and Bivigam remained weak [#PR-EARNINGS-2026-08-06]. Social coverage is unavailable, and missing analyst reaction is not treated as positive evidence. The setup is positive but monitoring-oriented.

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Bivigam competitive and pricing pressure
SG-001 pre-IND development milestone

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$11 / p=50% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.60

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-15
ACAAI real-world evidence update
ADMA submitted an abstract based on 127 Asceniv-treated primary-immunodeficiency patients reporting statistically significant reductions in infection-related hospitalizations and healthcare utilization. Positive reception could support payer and prescriber adoption [#SEC-8K-2026-08-05].
Prob 60.00% • Move 7.00% • Priced-in 25.00%
EVENT2026-12-31
Asceniv growth and FY2026 guidance execution
Q2 2026 revenue was $124.4 million, Asceniv revenue grew 24% year over year to $102.9 million, gross margin reached 69%, and FY2026 guidance was reiterated at $530-$560 million revenue and $265-$300 million adjusted EBITDA. Continued Asceniv utilization and margin delivery are the nearest rerating tests [#SEC-8K-2026-08-05].
Prob 70.00% • Move 10.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Bivigam competitive and pricing pressure
2026-12-31
Bivigam remains exposed to competitive dynamics, discounting, and pricing pressure in the standard immune-globulin market. Stabilization could fail to hold, leaving Asceniv to carry more of the growth burden [#SEC-8K-2026-05-06].
Prob 75% • Move -10% • Priced-in 60%

Long-term Catalysts

Months to a year

SG-001 pre-IND development milestone
2026-12-31
ADMA is progressing SG-001 and plans to submit a pre-IND meeting package to the FDA by year-end 2026. This is an early pipeline option whose value depends on regulatory and subsequent clinical progress [#10-K-2026-02-25].
Prob 45% • Move 10% • Priced-in 20%

Risks

Asceniv utilization growth or prescriber adoption could slow, weakening the main commercial growth driver.
Bivigam demand and pricing remain pressured by competition, discounting, and market supply dynamics.
Higher R&D and operating expenses could pressure near-term profitability.
No reliable post-earnings price reaction, analyst revision, options, short-interest, or social data was supplied.
SG-001 remains early-stage and its potential value depends on FDA interaction and future clinical progress.

Peers

Symbol	Summary
AUPH	Same-sector market-cap reference, but the packet does not establish direct product or operating overlap; useful only directionally.
HCM	Same-sector market-cap reference with limited demonstrated comparability to ADMA's commercial plasma-derived biologics model.
NUVB	Same-sector market-cap candidate, but its clinical-stage profile makes it a loose operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

AUPH

Same-sector market-cap reference, but the packet does not establish direct product or operating overlap; useful only directionally.

HCM

Same-sector market-cap reference with limited demonstrated comparability to ADMA's commercial plasma-derived biologics model.

NUVB

Same-sector market-cap candidate, but its clinical-stage profile makes it a loose operating peer.